• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Albright Jerry was granted 3,858 shares, increasing direct ownership by 55% to 10,832 units (SEC Form 4)

    6/18/25 8:16:24 PM ET
    $SWKH
    Diversified Financial Services
    Finance
    Get the next $SWKH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Albright Jerry

    (Last) (First) (Middle)
    5956 SHERRY LANE, SUITE 650

    (Street)
    DALLAS TX 75225

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SWK Holdings Corp [ SWKH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/16/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/16/2025 A 3,858(1) A $14.26 10,832 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Consists of shares of common stock issued in connection with the Reporting Person's voluntary decision to receive shares in lieu of cash compensation for his services as a director. The restricted shares vest on the earlier of (i) June 16, 2026, or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service through such vesting date.
    /s/ Jerry Albright 06/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SWKH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SWKH

    DatePrice TargetRatingAnalyst
    12/28/2022$26.00Buy
    Lake Street
    4/18/2022$26.00Buy
    Lake Street
    More analyst ratings

    $SWKH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hatcher Robert K. was granted 3,858 shares, increasing direct ownership by 30% to 16,662 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:16:45 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    Director Albright Jerry was granted 3,858 shares, increasing direct ownership by 55% to 10,832 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:16:24 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    Director Dotter Laurie L. was granted 3,858 shares, increasing direct ownership by 30% to 16,791 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:15:58 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

    Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin

    7/31/25 8:30:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    ImpediMed Secures $15m Growth Capital Funding

    New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv

    2/7/25 11:00:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

    January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

    1/22/25 8:30:00 AM ET
    $BDRX
    $JNJ
    $SWKH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Financial Services
    Finance

    $SWKH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on SWK Holdings with a new price target

    Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

    12/28/22 9:18:49 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Lake Street initiated coverage on SWK Holdings with a new price target

    Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

    4/18/22 8:44:23 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Leadership Updates

    Live Leadership Updates

    View All

    Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

    Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin

    7/31/25 8:30:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

    January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

    1/22/25 8:30:00 AM ET
    $BDRX
    $JNJ
    $SWKH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Financial Services
    Finance

    SWK Holdings Appoints Chief Financial Officer

    Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC

    7/8/24 5:00:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    SEC Filings

    View All

    SWK Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - SWK Holdings Corp (0001089907) (Filer)

    8/14/25 4:45:02 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form 10-Q filed by SWK Holdings Corporation

    10-Q - SWK Holdings Corp (0001089907) (Filer)

    8/14/25 4:43:49 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SWK Holdings Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - SWK Holdings Corp (0001089907) (Filer)

    7/17/25 5:04:20 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Financials

    Live finance-specific insights

    View All

    SWK Holdings Corporation Announces Financial Results for Third Quarter 2024

    Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2

    11/14/24 4:15:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SWK Holdings Provides Portfolio Update

    Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

    10/17/24 4:15:00 PM ET
    $BTCY
    $DERM
    $ELUT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

    DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

    7/17/24 4:15:00 PM ET
    $BIOL
    $BTCY
    $DERM
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SWKH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SWK Holdings Corporation

    SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

    11/14/24 11:49:47 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Amendment: SEC Form SC 13D/A filed by SWK Holdings Corporation

    SC 13D/A - SWK Holdings Corp (0001089907) (Subject)

    10/25/24 4:05:56 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form SC 13G/A filed by SWK Holdings Corporation (Amendment)

    SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

    2/14/24 2:14:12 PM ET
    $SWKH
    Diversified Financial Services
    Finance